Two Sigma Advisers LP Increases Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Two Sigma Advisers LP increased its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 12.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,702,200 shares of the company's stock after acquiring an additional 291,800 shares during the period. Two Sigma Advisers LP owned about 1.29% of Allogene Therapeutics worth $5,756,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. abrdn plc acquired a new stake in Allogene Therapeutics in the fourth quarter valued at approximately $776,000. Vontobel Holding Ltd. boosted its position in Allogene Therapeutics by 788.4% in the fourth quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company's stock valued at $416,000 after buying an additional 173,457 shares in the last quarter. Rhumbline Advisers boosted its position in Allogene Therapeutics by 10.1% in the fourth quarter. Rhumbline Advisers now owns 191,714 shares of the company's stock valued at $408,000 after buying an additional 17,527 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Allogene Therapeutics by 4.1% in the fourth quarter. Bank of New York Mellon Corp now owns 330,769 shares of the company's stock valued at $705,000 after buying an additional 13,150 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Allogene Therapeutics by 0.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,188,838 shares of the company's stock valued at $2,532,000 after acquiring an additional 9,990 shares during the last quarter. Institutional investors and hedge funds own 83.63% of the company's stock.

Allogene Therapeutics Stock Performance

ALLO stock traded down $0.04 during mid-day trading on Friday, reaching $1.15. 790,022 shares of the stock traded hands, compared to its average volume of 3,313,439. Allogene Therapeutics, Inc. has a one year low of $0.86 and a one year high of $3.78. The stock has a market capitalization of $250.45 million, a PE ratio of -0.73 and a beta of 0.60. The business has a 50-day moving average price of $1.36 and a two-hundred day moving average price of $1.80.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.28). On average, equities analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO David D. Chang sold 46,668 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the transaction, the chief executive officer now owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. This represents a 0.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 61,757 shares of company stock worth $115,873 over the last 90 days. 13.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ALLO shares. Canaccord Genuity Group reissued a "buy" rating and set a $14.00 target price on shares of Allogene Therapeutics in a research note on Friday, March 14th. Oppenheimer dropped their target price on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. Citizens Jmp cut shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 target price on shares of Allogene Therapeutics in a report on Wednesday, May 14th. Finally, Piper Sandler decreased their price target on shares of Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $8.44.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).